PTGX
Protagonist Therapeutics Inc
NASDAQ: PTGX · HEALTHCARE · BIOTECHNOLOGY
$98.52
-2.66% today
Updated 2026-04-29
Market cap
$6.34B
P/E ratio
—
P/S ratio
137.68x
EPS (TTM)
$-2.05
Dividend yield
—
52W range
$41 – $108
Volume
0.8M
Protagonist Therapeutics Inc (PTGX) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$98.52
12-Month target
—
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.0B | $0.0B | $0.1B | $0.4B | $0.0B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -282.80%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.